AstraZeneca PLC, a biopharmaceutical company, engages in the discovery, development, manufacturing, and marketing of prescription medicines. The company operates in approximately 100 countries. Marketed Products Respiratory, Inflammation and Autoimmunity ccolate (zafirlukast) is an oral leukotriene receptor antagonist for the treatment of asthma Bricanyl Respules (terbutaline) is a short-acting beta2-agonist administered via a nebuliser for acute treatment of asthma and chronic obstructive pulmonary disease (COPD) in both children and adults. Bricanyl Turbuhaler (terbutaline) is a short-acting beta2-agonist for the acute treatment of bronchial-obstructive symptoms in asthma and COPD. Daliresp (roflumilast) is an oral PDE4 (phosphodiesterase-4) inhibitor for adults with severe COPD to decrease their number of exacerbations (US only). Duaklir Genuair (aclidinium/formoterol in a dry powder inhaler) is a fixed dose combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic receptor agonist (LABA) for the maintenance treatment of COPD. Eklira Genuair/Tudorza/Bretaris (aclidinium in a dry powder inhaler) is a LAMA for the maintenance treatment of COPD. Oxis Turbuhaler (formoterol) is an onset, long-acting beta2-agonist for the treatment of bronchial-obstructive symptoms in asthma and COPD. Pulmicort Turbuhaler/Pulmicort Flexhaler (budesonide) is an inhaled corticosteroid for maintenance treatment of asthma. Pulmicort Respules (budesonide) is a corticosteroid, administered via a nebuliser, for the treatment of asthma in both children and adults. Rhinocort (budesonide) is a nasal steroid treatment for allergic rhinitis (hay fever), perennial rhinitis and nasal polyps. Symbicort pMDI (budesonide/ formoterol in a pressurised metered-dose inhaler) is a combination of an inhaled corticosteroid and a fast onset, long- acting beta2-agonist for maintenance treatment of asthma and COPD, including chronic bronchitis and emphysema in the US, Australia and some other markets. Symbicort Turbuhaler (budesonide/ formoterol in a dry powder inhaler) is a combination of an inhaled corticosteroid and a fast onset, long-acting beta2-agonist for the maintenance treatment of asthma and COPD. In asthma, it is also approved for Symbicort Maintenance And Reliever Therapy (Symbicort SMART). Symbicort Turbuhaler is approved in Europe, Japan and many other countries excluding the U.S. Cardiovascular and Metabolic diseases Cardiovascular disease Atacand1/Atacand HCT/Atacand Plus (candesartan cilexetil) is an angiotensin II antagonist for the 1st line treatment of hypertension and symptomatic heart failure. Brilinta/Brilique (ticagrelor) is an oral antiplatelet for acute coronary syndromes (ACS). Crestor2 (rosuvastatin calcium) is a statin for dyslipidaemia and hypercholesterolemia. Plendil (felodipine) is a calcium antagonist for hypertension and angina. Seloken/Toprol-XL (metoprolol succinate) is a beta-blocker once-daily tablet for control of hypertension, heart failure and angina. Tenormin3 (atenolol) is a beta-blocker for hypertension, angina pectoris and other CV disorders. Zestril4 (lisinopril dihydrate) is an angiotensin converting enzyme inhibitor for a range of CV diseases, including hypertension. Metabolic disease Bydureon (exenatide extended-release for injectable suspension) is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist available as a single-dose tray or a single-dose pen indicated to improve glycaemic control, in adults with Type 2 diabetes. Byetta (exenatide injection) is a twice-daily injectable GLP-1 receptor agonist indicated to improve glycaemic control in adults with Type 2 diabetes. Farxiga/Forxiga (dapagliflozin) is a selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2 inhibitor) indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes. Kombiglyze XR (saxagliptin and metformin hydrochloride extended release) combines saxagliptin (Onglyza) and extended release metformin (metformin XR) in a once-daily tablet for Type 2 d
astrazeneca plc-spons adr (AZN:New York)
2 Kingdom Street
London, W2 6BD
Phone: 44 20 7604 8000
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for AZN.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.